ReviewFrontiers in endocrinology2026
Patient-derived induced pluripotent stem cells for precision modelling of monogenic beta cell disorders.
Review in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Over the past several years, research and technologies involving patient-derived induced pluripotent stem cells (iPSCs) have rapidly advanced, enabling the study of various disease pathologies, including rare pathologies like monogenic disorders of beta cell function. iPSCs offer a unique model to study monogenic beta cell disorders such as Maturity-onset diabetes of the young (MODY) and congenital hyperinsulinism as they can be derived directly from patients with novel genetic variants and then differentiated into pancreatic progenitors and beta cells. Studies have used iPSC-derived SC-islets to demonstrate how transcription factor dysfunction can perturb insulin secretion, beta cell maturation, and endocrine lineage specification in MODY subtypes. Additional studies in congenital hyperinsulinism have utilized iPSC-derived SC-islets to model disease-specific hallmarks such as excess insulin secretion and increased beta cell proliferation. These studies provide the foundation for future studies using iPSC-derived SC-islets as a platform for elucidating mechanisms of how single-gene variants disrupt beta cell specification, maturation, and survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.